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ABSTRACT OF THESIS

INVESTIGATION OF THIOL-CONTAINING BIOMARKERS AND THEIR ROLE
IN THE EXPOSOME
Exposomics is an emerging area of study that looks at how the environment
around a person or persons affects their overall health. Biomarkers have emerged
as useful tools to better understand how the exposome affects a person. In this
work, we investigate two potential endogenous biomarkers, homocysteine and
glutathione that have been previously implicated in a number of diseases that have
been linked to environmental causes. We also investigated an environmental
exposure, the fungicide Ziram, which epidemiologically has been linked to
diseases. In our investigation, we utilized capillary electrophoresis and capillary
electrophoresis-mass spectrometry to develop a method for homocysteine and
identify a derivative to keep it from auto-oxidizing. We utilized mass spectrometry
to identify the best ionization technique to detect Ziram and confirmation of where
it binds on thiol-containing molecules. We also developed a method to extract
glutathione-Ziram from serum and utilized liquid chromatography-mass
spectrometry to begin a validation of glutathione-Ziram. Although future work is
needed, we believe that this work was the beginning steps to understand
biomarkers and their role in the exposome.
KEYWORDS: Exposome, Biomarkers, Ziram, Capillary Electrophoresis, Mass
Spectrometry, Liquid Chromatography
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CHAPTER 1. INTRODUCTION
EXPOSOME
Christopher Paul Wild first coined the word ‘exposome’ in 2005 to describe
the effect the environment has on the human genome and the potential for
disease and disorder development.1 The exposome entails the life-course
exposures that include everything from where we live to what we eat throughout
our life from the prenatal to death.1,2 There are three categories of the exposome,
the internal, general external, and specific external.1–3 The internal environment
encompasses things like metabolism, endogenous hormones, gut microflora, and
other things that are internal to a specific person.2 The specific external has to do
with things like lifestyle factors, diet, environmental pollutants, and the general
external involves socioeconomic status, urban-rural environment, and climate to
name a few.2 All three categories are not mutually exclusive, but rather give an
idea as to what a potential exposure is for a person and how that exposure can
affect them and others in similar situations. Being able to understand the
epidemiology and role a person’s environment can play on their health, could
potentially link these complex health issues and how to understand them more.
There are two different approaches to measuring a person’s exposome, a
bottom-up and top-down approach. The bottom-up approach essentially looks at
particular chemicals of every individual ‘exposure’ (e.g. diet, pollution, etc) at
multiple time points in a person’s life. Although this approach would be able to
identify particular exposures, it would not take into account the internal
environment and its role in the exposome. The top-down approach, on the other
1

hand, would look at all chemicals, or their metabolites, in the blood of an
individual.4 One of the main advantages of this approach is that the exposure
chemical could be monitored directly and/or the downstream effects of it. These
downstream effects lead to signatures and biomarkers, which could ultimately
lead to an understanding of disease progression.4 The discovery and usage of
biomarkers, which aid in monitoring normal biological processes and pathogenic
progression, has grown over the decades.5–7 However, the issue with intersecting
the exposome with diseases while using biomarkers, is trying to intersect the
biomarkers of a disease with the biomarkers of an exposure.
For instance, Parkinson’s Disease etiology has three different
components: genetic-, age-, and environmental-related, so trying to establish a
biomarker that can be indicative of Parkinson’s Disease across all three
components is difficult.8 There may be one biomarker within the body that
indicates the potential for Parkinson’s development from a genomic perspective,
and another exogenous biomarker indicative of Parkinson’s from an
environmental side. In some instances, the interaction between an exogenous
and endogenous biomarker could be utilized in disease progression research. In
this work, two endogenous and one exogenous biomarkers were investigated,
homocysteine (HCYS), glutathione (GSH), and Ziram, respectively. Both
homocysteine and glutathione have been implicated in a number of biological
processes that can ultimately lead to diseases. The interaction between Ziram
and glutathione was investigated to combine the exposome with biological
processes in potential disease progression.
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ANALYTICAL TECHNIQUES
One of the things to consider when looking at biomarkers is what type of
separation technique to use for both qualitative and quantitative analysis. In this
work, two separation techniques were used to look at the potential biomarkers of
homocysteine and glutathione. These techniques were Capillary Electrophoresis
(CE)/Capillary Electrophoresis-Mass Spectrometry (CE-MS) and Liquid
Chromatography (LC)/Liquid Chromatography-Mass Spectrometry (LC-MS).

Capillary Electrophoresis
Capillary electrophoresis (CE) is a separation technique that utilizes the
ionization capabilities of the solute. A strong electric field is applied across the
running buffer, allowing the ions to migrate depending on their size and electric
charge.11 The advantages of CE is the short analysis time, high efficiency, small
sample and separation buffer volumes, and ease of changing the separation
buffer.11 The movement of the ions is a balancing act between the electromotive
forces and frictional forces of the ion in the solution.12 A CE apparatus contains a
very thin fused silica capillary suspended between two buffer solutions and a
high-voltage power supply that is able to apply a separation voltage.11,12 Although
CE has become more advanced, there are a few aspects to take into
consideration when using this technique. One such aspect is the electroosmotic
flow, or EOF. The inside of the capillary is covered with silanol groups that
generally carry a negative charge due to the deprotonation of these groups.11,12
Because of this negative charge, the cations in the solutions end up forming a
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double layer, where the first layer is mostly immobilized due to the electrostatic
interaction with the wall, and the second layer is more mobile and thus, along
with the surrounding water molecules, are able to migrate to the cathode when
the voltage is applied.11,12 The water molecules cause the whole solution in the
capillary to be dragged forward, generating a net flow across the capillary.12 This
flow allows the sample to move through the column more efficiently similarly to a
plug, becoming an advantage over the parabolic shape flow that occurs in HPLC,
eliminating band broadening.11,12 However, one downfall to this phenomenon is if
the EOF exceeds the mobilities of the ions, specifically the anions, all ions will be
pushed towards the detection causing the analysis of both cations and anions.12
However, the EOF can be altered by adjusting the pH of the running buffer, the
viscosity of the solution, adding a radial field, adding a surfactant, or adding
organic solvents.11

Liquid Chromatography
Liquid chromatography is a physical separation technique with a liquid
mobile phase and a stationary phase bed. The separation occurs based on
sorption and desorption of the analyte with the stationary phase.13 There are
many separation mechanisms, e.g. ion-exchange, size-exclusion, and
adsorption, but most LC systems are the result of a mixture. Originally,
chromatography utilized a polar stationary phase and a non-polar mobile phase
called normal-phase chromatography.13,14 However, as the technique has
evolved, more and more LC systems utilize the reverse-phase chromatography,
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which involves a non-polar stationary phase and a polar mobile phase. The
stationary phase usually consists of a chemically bonded long hydrocarbon chain
linked to a solid surface of silica.13,14 Some examples of these hydrocarbon
chains are C8 and C18. These cause the main interaction between the stationary
phase and analytes to be the hydrophobic forces. The retention of the analyte on
the stationary phase depends on the surface area between the two. Thus,
analytes with larger hydrophobic surface areas tend to stay longer on the column
than smaller analytes.13,14
The basic components of a liquid chromatography system are a solvent
supply system, a pumping system, an injector, the column, and a detector.13,14
The solvent supply system supplies the solvent to the system that acts as the
mobile phase. The pumping system not only pumps the solvent through the
system but also helps deliver a constant flow through the injector, column, and to
the detector. The injector adds the mobile phase to a small volume of the analyte
which is then injected onto the column. The column is where the actual
separation occurs, and the detector is how the analyte is measured. Some
systems are interfaced to a separate instrument that adds another identification
ability. This is usually in terms of a mass spectrometer.

Mass Spectrometry
Mass spectrometry has been coupled to many separation techniques to
allow greater identification of molecules. In the case of both capillary
electrophoresis and liquid chromatography, the liquid mobile phase is converted
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to gas-phase ions where the analytes are further analyzed with the mass
analyzer. Over the past few decades, the main ionization sources utilized in
mass spectrometry are Atmospheric Pressure Chemical Ionization (APCI) and
Electrospray Ionization (ESI).14,15 APCI was utilized as the main ionization source
before ESI erupted in the field of LC-MS. Both ionization sources use some type
of ionizing agent, e.g. reagent gaseous ions or high electric field, to energize the
analyte for analysis. APCI and ESI are both considered soft ionization sources
because when the analyte is impacted with the energy source, there is less
fragmentation compared to hard sources and the molecular weight ion is seen in
the spectrum.15,16 The ionization in APCI occurs by collision with ions produced
by electron bombardment of a reagent gas.16 In the case of ESI, an analyte
moves through a charged capillary causing ionization of the analyte.17
Besides the ionization source, mass spectrometers follow a similar
breakdown in their components. There is the inlet source, the ion source, the
mass analyzer, the ion transducer, and the signal processor.16 The inlet source is
how the sample is introduced into the mass spectrometer. It is usually coupled to
a separation technique via tubing. The ion source is where the actual ionization
of the analyte occurs. In both APCI and ESI, the ionization sources are at
atmospheric pressure. The mass analyzer and ion transducer are contained
within a vacuum pump system. The mass analyzer is similar to a filter that
funnels the ions towards the transducer and can filter them based on their massto-charge (m/z) ratio. The transducer converts the charged ions into electrical
signals that can be processed by the computer.16

6

In this work, we attempted to identify analytical techniques for the
identification of homocysteine, glutathione, Ziram, and the interaction of
glutathione with Ziram. We utilized both Capillary Electrophoresis/Capillary
Electrophoresis-Mass Spectrometry and Liquid Chromatography-Mass
Spectrometry to measure the three compounds.
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CHAPTER 2. HOMOCYSTEINE IDENTIFICATION VIA CAPILLARY
ELECTROPHORESIS AND CAPILLARY ELECTROPHORESIS-MASS
SPECTROMETRY
INTRODUCTION
Homocysteine is a noncanonical sulfur-containing amino acid that is not
received through the diet, like other essential amino acids, nor is used to create
proteins. However, homocysteine is created solely from methionine (Figure 2.1)
as part of the methionine cycle, is converted into cysteine via the transsulfuration
pathway, and can also be cyclized to form homocysteine thiolactone.
Homocysteine (HCYS) has the chemical formula of C4H9NO2S, which is similar to
cysteine, minus a methyl group, so the two homologues share chemical
similarities (Figure 2.1). The main similarity between homocysteine and cysteine
is the electronegative sulfur at the end of the side chain that can easily form
disulfide bonds.

a)
H 2N

b)

O
CH
CH2
CH2

C

OH

H 2N

c)

O
CH

C

OH

H 2N

O
CH

C

OH

CH2

CH2

CH2

SH

S

SH

CH3

Figure 2.1 Structure of a) homocysteine, b) cysteine, and c) methionine
Methionine with adenosine triphosphate (ATP) is activated by methionine
adenosyltransferase (MAT) to form S-adenosylmethionine (SAM/AdoMet), which
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is used as a universal methyl donor. SAM is converted to Sadenosylhomocysteine (SAH/AdoHcy) after donating a methyl group to DNA,
RNA, and other proteins. SAH is then hydrolyzed to homocysteine and
adenosine via SAH hydrolase (SAHH).18 Homocysteine is then irreversibly
converted to cysteine via the transsulfuration pathway. Homocysteine condenses
with serine to form cystathionine catalyzed by the pyridoxal-5’-phosphate (PLP)containing enzyme, cystathionine β-synthase (CBS). Cystathionine is then
hydrolyzed to cysteine and α-ketobutyrate via a second PLP enzyme, γcystathionase (CTH).19,20
Besides being converted to cysteine as a regulatory mechanism,
homocysteine can be remethylated back to methionine via two pathways. The
first is a vitamin-B12 independent reaction where betaine has a methyl
transferred to HCYS via betaine-homocysteine methyltransferase. The second is
a vitamin-B12 dependent reaction where methionine synthase moves a methyl
from 5-methyl tetrahydrofolate to HCYS. This leads to the formation of
tetrahydrofolate (THF) as a byproduct that can be converted back to 5-methyl
THF. The first reaction occurs in all tissues while the second occurs in the
kidneys and liver.18–20 All of these pathways (Figure 2.2) are impacted by the Bvitamin family.19,20 Because these pathways are so intricate, one misstep can
cause a multitude of issues like diseases.
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Figure 2.2 Homocysteine metabolism18
Homocysteine and diseases
Homocysteine, although not a canonical amino acid, has been implicated
as a biomarker in many diseases, such as cardiovascular diseases, autoimmune
diseases, neurodegenerative diseases, and many more. Because HCYS is an
intermediate in many pathways (Figure 2.2), any major concentration changes
can indicate the progression of a disease or the likelihood of the development of
a disease. Since homocysteine metabolism is considered part of the folate
(vitamin B9) and cobalamin (Vitamin B12) pathways, if there is a deficiency in
10

either one of these vitamins or B6, there can be an increase in cellular
homocysteine.9,21 As previously mentioned, there are mechanisms to lower
HCYS levels in the cells. However, there can be issues if there are errors in the
mechanism of HCYS metabolism, namely elevated levels of HCYS is referred to
as hyperhomocysteinemia which can lead to homocystinuria, the inability to
breakdown methionine.9
In the 1960s, a publication by K. McCully described vascular legions in
two patients with homocystinuria. One was due to CBS deficiency and the other
was due to a defect in cobalamin metabolism.9,22 Further cohort and ex vivo
studies showed that elevated levels of HCYS is indicative of an increased risk of
vascular disease. It has been shown that homocystinuria causes endothelial
dysfunction and is due to reduced bioavailability of nitric oxide.22
Homocysteine has been implicated in other health issues like cognitive
decline and diseases. Whether homocysteine plays a direct role in cognitive
issues or is just an indication of the decline is unclear because of the involvement
of the B-vitamins. Duan et al. compared increasing homocysteine levels in mice
and human dopaminergic cell culture to determine their effect on dopaminergic
neurons.23 They did not see a direct correlation between folate, homocysteine
levels, and neuronal damage; but, they did see that the neurons became more
susceptible to known Parkinson’s-causing toxins MPTP and rotenone.23 Another
group, Isobe et al, investigated homocysteine metabolites and their effect on
neurons. One of the products homocysteine is metabolized to is homocysteic
acid, which is structurally similar to glutamate. Homocysteic acid activates the N-
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methyl-D-aspartate (NMDA) receptor similarly to glutamate, causing apoptosis of
the neurons.24 They also saw that with activation of the NMDA receptor from
homocysteic acid, the glutamate concentration increases, causing a reduction in
glutathione, which leads to oxidative stress and ultimately apoptosis of the
neurons.24
Although there have not been any major defining studies implicating
homocysteine’s causation of diseases, there have been implications that a higher
concentration means a greater susceptibility to many diseases. As a person
ages, homocysteine levels also decrease, which only adds to the complexity of
neurological decline and the development of other diseases. Normal
homocysteine levels in blood and plasma are approximately 4-15 µM, so any
deviation from this range can be quick and potentially detrimental.22,23 In this
experiment, we attempted to identify homocysteine through capillary
electrophoresis (CE) and capillary electrophoresis-mass spectrometry (CE-MS).
We attempted to differentiate HCYS from the other sulfur-containing amino acids,
cysteine and methionine utilizing CE and CE-MS.

MATERIALS AND METHODS
We used the Beckman Coulter P/ACE MDQ Capillary Electrophoresis
System with a Didode array detector with a Polymicro technology column with an
internal diameter of 50 µm and 32 Karat software. We also used the Groton
Biosystems Crystal CE GPA100 system coupled to the Finnegan LCQ Deca
Mass Spectrometer with Xcalibur software. We adjusted the Hudson protocol for
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the capillary electrophoresis parameters.25 For the Beckman Coulter CE, we
conditioned the column every day that a sample was to be run under the
conditions in Table 2.1.
Table 2.1 Column conditioning parameters for Capillary Electrophoresis
Event
Value
Duration
Inlet Vial
Outlet Vial
Rinse50 psi
5.00 min
Methanol
BGE
Pressure
out/waste
Rinse50 psi
5.00 min
DI Water
BGE
Pressure
out/waste
Rinse50 psi
2.00 min
1 M NaOH
BGE
Pressure
out/waste
Rinse50 psi
5.00 min
DI Water
BGE
Pressure
out/waste
Rinse50 psi
5.00 min
BGE buffer
BGE
Pressure
out/waste
Separate50 psi
30.00 min
BGE buffer
BGE
Pressure
out/waste
The background electrolyte (BGE) buffer consisted of 192.5 µL formic acid
in 100 mL deionized water with the pH adjusted to 2.85 with 50 mM ammonium
formate. Samples were run under the conditions in Table 2.2. An absorbance at
214 nm was used for all compounds. There was a multi-view screen to ensure
that an absorbance was seen.
Table 2.2 Run parameters for Capillary Electrophoresis
Event
Value
Duration
Inlet Vial
Rinse30 psi
5.00 min
BGE buffer
Pressure
Rinse10 psi
5.00 min
BGE buffer
Pressure
Inject0.7 psi
15.0 sec
Sample
Pressure
Inject0.5 psi
10.0 sec
BGE buffer
pressure
Separate25.0 kV
20.00 min
BGE buffer
Voltage
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Outlet Vial
BGE out
BGE out
BGE
out/waste
BGE
out/waste
BGE out

For the Groton-Finnegan system, the column was also conditioned every
day a sample was going to be run under the following condition: 1 M NaOH, 1000
mbar, 0.0 kV, 3.00 min. The samples were ran under the conditions in Table 2.3.
Table 2.3 Run parameters for Capillary Electrophoresis-Mass Spectrometry
Vial
Pressure
Voltage
Time
BGE buffer
1000 mbar
5.0 kV
3.00 min
Sample
100 mbar
5.0 kV
0.20 min
BGE buffer
50 mbar
25.0 kV
20.00 min
RESULTS AND DISCUSSIONS
Because homocysteine has an overall negative charge due to the terminal
sulfur, capillary electrophoresis is a good candidate for an analytical technique.
Based on the Hudson protocol, we used lidocaine to assess the parameters in
the protocol before attempting with HCYS.25 According to the protocol, the
conditions for sample separation include working at a pressure of 50 and 75psi.
Our system does not operate at that high of a pressure, so we used lidocaine to
assess if our given pressure of 30psi would be sufficient. We also assessed the
pressure and voltage applied over the course of the separation. Once all of the
parameters were established for lidocaine, we started sampling homocysteine.
As seen in Figure 2.3, we were able to get a good separation of homocysteine at
an elution time of about eight minutes.
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Figure 2.3 Electropherogram of homocysteine
Although the main goal of our experiment was to identify and potentially
quantify homocysteine, we needed to consider similar compounds. These
compounds included methionine, which homocysteine is part of that cycle, and
cysteine, since homocysteine varies structurally by one methyl group. We looked
at each one individually, then as homocysteine plus one of the others, and then
as a combination of all three. As seen in Figure 2.4, all the compounds migrated
about the same time with less than a half-minute difference. The inverted peak in
both Figure 2.3 and 2.4 is due to a difference in the molar absorptivity coefficient
from Beer’s Law. This could be due to the buffer absorbing better than the
sample at the given wavelength. Since there was no differentiation between the
three compounds, we looked to adding a derivatizing agent.
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Methionine
Cysteine
Homocysteine
Methionine + Cysteine + Homocysteine

Figure 2.4 Electropherogram of cysteine, homocysteine, and methionine
We started looking at previous derivatizing agents that have been used
with homocysteine, including 4-vinylpyridine. We originally started out at a 1:1
mixture of 4-vinylpyridine to homocysteine, but the 4-vinylpyridine overtook the
trace. Even after lowering the ratio of 4-vinylpyridine to homocysteine, the CE
trace was still overpowered by the 4-vinylpyridine. Another derivatizing agent we
looked at was N-ethylmaleimide (NEM, Figure 2.5), which has been shown to be
an irreversible derivative that attaches to the sulfur across the double bond in
sulfur-containing compounds.26 Although there was a peak when HCYS and
NEM was ran on the CE, determining if the two molecules were actually
combining was difficult. Therefore, the CE-MS was used to confirm that the
compound was being formed. With a molecular weight of 260.31 g/mol, we used
the CE-MS to look for the m/z indicating that compound. Our parameters for the
CE-MS were as close to the CE as we could get, so that the differences between
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the two instruments were miniscule. As seen in Figure 2.6, we were able to see
the 261.3 m/z indicating that the NEM was attaching to the HCYS.

O
N
O

Figure 2.5 Structure of N-ethylmaleimide

Figure 2.6 Capillary Electrophoresis Mass Spectrum of homocysteine plus Nethylmaleimide
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CONCLUSION
Homocysteine has emerged as a potential endogenous biomarker in a
multitude of biological issues and diseases despite being a non-canonical amino
acid. Because of the terminal sulfur group, capillary electrophoresis was utilized
as the analytical technique to identify it. Even though we were able to identify
HCYS via CE individually, the identification was made more difficult with the
addition of similar compounds cysteine and methionine. This led to the
investigation of using a derivatizing agent. The first one, 4-vinylpyridine,
overpowered HCYS in the system, so we investigated the use of Nethylmaleimide. It was unclear if the HCYS and NEM were actually binding via
use of the CE, so we coupled mass spectrometry with the CE to confirm.
Through CE-MS, we were able to see the mass-to-charge ratio indicative of
HCYS-NEM.

18

CHAPTER 3. ZIRAM IDENTIFICATION VIA LIQUID CHROMATOGRAPHYMASS SPECTROMETRY
INTRODUCTION
Zinc (bis)dimethyldithiocarbamate, commonly known as Ziram (ZIR), is a
potent fungicide of the dithiocarbamate (DTC) fungicide family. It includes
Thiram, Zineb, Maneb, and many others. Dithiocarbamates were first discovered
as plant fungicides in the 1930s and first used during World War II.27 They have
been used as plant fungicides, animal repellants, and in some cases as
accelerants in the rubber industry.27 Ziram is part of a subset within this family of
fungicides, the dialkyldithiocarbamates. One of the main features of these
fungicides is the two sulfur groups that are highly reactive as seen in Figure 3.1.
In some cases, like Ziram, they can act as chelating agents with a transition
metal ion like zinc, manganese, and iron. These multisite interactions of these
compounds give them an advantage to influence the biological activities of
different proteins, enzymes, and exert pro-oxidant and, in some cases,
antioxidant effects.27,28
S

S
Zn

N
S

N
S

Figure 3.1 Structure of Ziram
The main toxicological effects of the DTC group is due to their lipophilic
nature, allowing them to be easily absorbed through the skin, ingested, inhaled,
and the ability to cross cell membranes.27 This capability, along with the chelation
aspect, leads to the redistribution of heavy metals throughout the brain.28
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Metabolically, DTCs undergo detoxification via S-glucuronidation or biodegrade
to many metabolites such as carbon disulfide, thiourea, alkylamines,
ethyleneamines, and many others.27,28 Carbon disulfide is a general neuropathic
agent and ethylenethiourea, a biproduct of ethylenebis dithiocarbamates, has
antithyroid and carcinogenic effects.27,28 There have also been studies on some
of the DTC molecules that show they exhibit both antioxidant as well as prooxidant effects.27
Ziram, and other dithiocarbamates, have been implicated in having a role
in the development of Parkinson’s disease among other diseases. Multiple
epidemiology studies looking at farm workers exposed to Ziram indicated that a
higher incidence of Parkinson’s or Parkinson-like symptoms occur later on in life
compared to those not exposed to Ziram.29,30 Because DTCs have reactive
sulfurs, an inference can be made that they are highly reactive to molecules with
sulfurs, like homocysteine and glutathione.
Although there are new and emerging studies on the dithiocarbamates
and their role in disease development and the exposome, there is a wide array of
how to study these fungicides as potential biomarkers. In this study, we first
investigated different ionization techniques to study Ziram, Electrospray
Ionization (ESI) and Atmospheric Pressure Chemical Ionization (APCI) in positive
and negative mode. We then looked at potential endogenous biomolecules,
glutathione and insulin, that could interact with Ziram via Liquid ChromatographyMass Spectrometry.
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MATERIALS AND METHODS
We used a Hewlett Packard series 1100 Liquid Chromatography system
connected to a Mass Spectrometer Detector with Agilent ChemStation Software.
We also used a Thermo Finnegan LTQ Mass Spectrometer and a Shimadzu
Nexera Liquid Chromatographer coupled to a Thermo Q-Exactive (QE) Orbitrap
Mass Spectrometer with a high temperature ESI source (HESI). Both the LTQ
and Q-Exactive Mass Spectrometers were used with Xcalibur software. Infusion
experiments on the LTQ utilized a syringe pump with a flow rate of 5 μL per
minute. The spray voltage was set to 4.5 kV, the source current was 14 μA, the
sheath auxiliary gas flow was 2 (arbitrary units), and the inlet temperature was
250°C. The QE infusion experiments had a spray voltage set to 3.5-4 kV, the
source current was 0.9 μA, the sheath auxillary gas flow was 2.8 arbitrary units,
and the syringe pump flow rate was 3 μL per minute.

ESI versus APCI for Ziram detection
A 1 mg/mL stock solution of Ziram in acetonitrile was diluted 1:10 in
acetonitrile. The 1:10 diluted Ziram was injected on the HPLC under positive and
negative mode for both ESI and APCI. Peak height, shape, area, and mass-tocharge ratios were evaluated to determine which ionization technique would be
optimal. The fragmentor, gain, gas temperature, voltage capillary, and nebulizer
pressure were also investigated.
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Glutathione binding of Ziram
Following the Kawakishi, S. et al protocol, 0.6 mmol of glutathione and 12
mmol of phenyl-isothiocyanate was mixed in 5 mL deionized water. The pH was
adjusted to 6 with HCl and NaOH, vortexed, and placed in a 70°C water bath for
five hours. Ethyl acetate (2 mL) was added to the sample where it was then
vortexed and centrifuged for two minutes. The ethyl acetate top layer was
removed and the lower water layer was injected via flow injection analysis onto
the LTQ.31 The same protocol was followed with a mixture of 4 millimolar
glutathione and 80 millimolar Ziram in water.
We made a solution of glutathione (0.1 mmol) and Ziram (20 mmol) in 2
mL sodium phosphate buffer, pH 6 (10.105 g sodium phosphate dibasic, 1.697 g
sodium phosphate monobasic, pH adjusted with HCl, and diluted to 500 mL with
water). Along with a glutathione control, both samples were placed in a 37°C
water bath. Starting at four hours, 100 microliters were removed, extracted with
50 microliters ethyl acetate, diluted with 50 microliters water, and infused on the
LTQ every hour until seven hours.

Insulin binding of Ziram
The same protocol for the glutathione with Ziram was followed with 0.1
mmol insulin and 20 mmol Ziram in sodium phosphate buffer. An insulin control
was included with the sample, and both were incubated in a 37°C water bath for
at least six hours. Ethyl acetate (200 μL) was added to 400 μL of sample, then
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vortexed and centrifuged for two minutes. The ethyl acetate layer was removed
and diluted with 400 μL water before infused on the LTQ.
To cleave insulin, the University of Washington Proteomics Research
protocol was used.32 Briefly, several mg/mL of insulin in 100 mM ammonium
bicarbonate and 8 M urea was incubated with dithiothreitol (final concentration of
5 mM) for 25-45 min at 56°C. The control was cooled to room temperature and
spun down to collect the condensation. Ziram was added to one half of the
control, and both the sample and control were incubated at 37°C for about an
hour. The samples were diluted by a factor of 10 with 50:50 methanol:water and
injected on the LTQ then for multiply charged ion confirmation on the Q-Exactive.

RESULTS AND DISCUSSION
ESI versus APCI for Ziram detection
In the review by Crnogorac et al., different analytical techniques used to
detect a number of dithiocarbamates was discussed.33 Among the techniques
included electrospray ionization and atmospheric pressure chemical ionization,
both in positive and negative mode. Each technique has pros and cons and
seemed to give reliable results in the review. We wanted to test this out for Ziram
specifically to determine which ionization technique and in which mode would
yield better results. Although each technique was able to give us indicative peaks
of Ziram, the main m/z ratio we were looking for was 120, which is just the
dithiocarbamate of Ziram. Each ionization mode gave good indicative total ion
chromatograms, with similar peak areas, shape, and height. However, the total

23

ion chromatogram of positive ESI was slightly better than the others (Figure 3.2).
When looking at the average area and height for the total ion chromatograms
and extracted ion chromatograms for m/z 120, ESI positive was slightly higher
with less variation compared to the others (Table 3.1). Also, taking into
consideration potential outside laboratories undertaking similar problems, most
laboratories have at least instruments with ESI capabilities compared to APCI.

Figure 3.2 Chromatograms of ESI negative, ESI positive, APCI negative, and
APCI positive
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Table 3.1 Average area and height for APCI negative, APCI positive, ESI
negative, and ESI positive
Area

APCI neg
APCI pos
ESI neg
ESI pos

APCI neg
APCI pos
ESI neg
ESI pos

Average
22204.08
432753.04
36493.86
463484.05

Average
4859.48
82216.24
7478.46
88366.68

TIC

TIC

Std dev
28644.45
374569.19
47277.41
211371.49
Height
Std dev
5592.3
71831.25
8532.38
91177.11

120 m/z
Average
Std dev
13721.3
16904.23
39793.78
54258.24
6171.41
4789.67
32352.23
25136.78
120 m/z
Average
Std dev
2893.1
3219.26
10169.04
13664.54
1699.22
1033.11
7368.09
5630.78

We also investigated within each technique some of the parameters
involved, including the fragmentor value, the gain, gas temperature, voltage
capillary, and nebulizer pressure. Overall peak shape, peak area, peak height,
and overall mass-to-charge fragmentation were evaluated. For positive mode
ESI, the optimal values we determined were 120 for the fragmentor, a 1.5 gain,
30 psig nebulizer pressure, and 300°C gas temperature (Table 3.2).
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Table 3.2 Optimized ESI and APCI parameters
Parameter
ESI positive ESI negative APCI
positive
Drying gas
11 L/min
11 L/min
11 L/min
flow
Nebulizer
30 psig
30 psig
30 psig
pressure
Drying gas
300°C
300°C
300°C
temperature
Capillary
3500 V
3000 V
3000 V
voltage
Gain
1.5
1.5
N/A
Fragmentor
120
120
N/A
Corona
N/A
N/A
4.0 μA
Current

APCI
negative
11 L/min
30 psig
300°C
3000 V
N/A
N/A
15 μA

Glutathione binding of Ziram
When we first started investigating Ziram, we wanted to look at potential
endogenous biomarkers that would bind and carry the fungicide throughout the
body. Because Ziram has the two reactive sulfurs, the molecules investigated
would need to be endogenous to the human body and contain a sulfur to ensure
that binding of Ziram to the molecule would most likely occur. This was also to be
varied by looking at low-, medium-, and high-molecular weight molecules.
Glutathione (Figure 3.3) was investigated as the low-molecular weight (307.32
g/mol) molecule. Research has indicated that dithiocarbamates, like Ziram, would
bind to other molecules via disulfide bonds, so glutathione, which contains one
cysteine, was a viable candidate to investigate. To test this, we used the paper
by Kawakishi, S. et al., where they used allyl isothiocyanate and glutathione.31 In
our experiment, we used phenyl isothiocyanate and once injected on the LC-MS,
major m/z peaks at 330 and 449 were observed. The 330 m/z ratio was attributed
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to glutathione plus sodium, and the 449 m/z ratio was attributed to glutathione
plus phenyl isocyanate and sodium. When we followed the same experiment with
Ziram and allowed the solution to incubate for up to 7 hours, there was a change
in the spectrum over the time frame. At zero-hour incubation, there were
indicative peaks for glutathione and Ziram by themselves (Figure 3.4a and b). At
the seven-hour mark, the m/z ratio of 120 revealing that Ziram and GSH were
bonding (Figure 3.4c). It was speculative at this point that the two molecules
were bonding at the sulfurs.
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Figure 3.3 Structure of a) glutathione and b) glutathione disulfide
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Figure 3.4 Mass spectra of a) glutathione before addition of Ziram, b) glutathione
plus Ziram at 0 hours, and c) glutathione plus Ziram at 7 hours
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The effect that the incubation time and temperature had on the binding and
spectrum of the glutathione-Ziram (GSH-ZIR) solution was also examined. At the
four-hour mark in the 70°C water bath, there were multiple ions indicative of
glutathione plus Ziram. In comparison, a lower water bath temperature and
longer incubation time was preferential for getting the indicative spectrum of
GSH-ZIR. However, with both temperatures, there was a lot of extra peaks that
were not easily identifiable as GSH, ZIR, or both.
We then injected the glutathione-Ziram mixture on the LTQ to look at the
fragment ions to confirm that the Ziram was attaching to the sulfur in glutathione.
The major ions seen in the LTQ were Ziram plus glutathione and sodium and a
peak indicative of cysteine and Ziram plus sodium, Figure 3.5. Although the 308
m/z for GSH was seen in the spectrum, after the addition of Ziram, the relative
abundance went down compared to before Ziram was added (Figure 3.6). The
opposite was seen with the GSH-ZIR m/z of 427, which was more prevalent in
the post-Ziram addition sample (Figure 3.7). Theoretically, GSH and Ziram
should attach via a disulfide bond. However, the spectrum from the LTQ was not
confirmatory, so the GSH-ZIR solution was infused onto the Q-Exactive and
underwent tandem mass spectrometry. Under tandem mass spectrometry, GSH
fragments at the peptide bonds. Ideally, even with the addition of Ziram attached
at the cysteine, GSH-ZIR should still fragment at the peptide bonds. As seen in
Figure 3.8, fragmentation at the glycine-cysteine peptide bond gives a peak at
352.05 m/z. In Figure 3.9, the fragmenting at the glutamic acid and cysteine bond
gives a peak at 297.04 m/z. Because there were no fragmentation peaks
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suggesting that Ziram attached at any other place on GSH, we concluded that
Ziram does attach at the sulfur in the cysteine.

427.0

Figure 3.5 Full mass spectra from the LTQ of a) glutathione and b) glutathione
plus Ziram
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Figure 3.6 Mass spectra of 308 m/z for a) glutathione and b) glutathione plus
Ziram

Figure 3.7 Mass spectra of 427 m/z for a) glutathione and b) glutathione plus
Ziram
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Figure 3.8 a) Mass spectrum 353.05 m/z and b) fragmentation of 353.05m/z
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a)

b)

Figure 3.9 a) Mass spectrum of 297.04 m/z and b) fragmentation of 297.04 m/z
Insulin binding of Ziram
With the success of seeing Ziram bind to GSH, insulin was investigated
next as the medium-sized molecular weight molecule. Insulin has a total
molecular weight of 5733.62 g/mol and is made up of two chains, the a-chain and
b-chain. The a-chain has a molecular weight of 2338.00 g/mol and four cysteine
molecules. Two of the sulfurs connect to two cysteinyl sulfurs in the b-chain,
which has a molecular weight of 3397.72 g/mol. Based on the results of GSH and
Ziram, insulin could bind up to six Ziram at each sulfur. We followed the same
experiment as GSH-ZIR to confirm that Ziram attaches to the cysteines in insulin;
however, since insulin is heavier than GSH, we could not differentiate if Ziram
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was attaching at the sulfurs or not on the LTQ. Because of this, we wanted to see
if cleaving the two chains apart may enable us to see whether Ziram was binding
at the cysteines or not. Following the WWPR-Proteomics Research Protocol, we
were able to see what appeared to be multiply charged ions on the LTQ.32
Although the LTQ was most likely showing multiply-charged ions, the Xcalibur
software did not enable deconvolution (Figure 3.10). The insulin and insulin plus
Ziram solutions were then infused on the Q-Exactive, which has similar software
to the LTQ but can deconvolute spectra to show multiply charged ions in their
singly charged states. After deconvolution, the spectrum showed that Ziram was
attaching to the a-chain (Figure 3.11), b-chain (Figure 3.12), and the whole
insulin molecule (Figure 3.13). However, if Ziram was truly attaching at the
cysteines was unclear and further research would need to be done to breakdown
the chains into smaller sections to confirm the actual location of Ziram binding to
insulin. Some studies suggested that Ziram may cause reactive oxygen species
with glutathione, especially in the brain, so further experiments were done with
glutathione as the peptide of study.
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Figure 3.10 Mass spectra of a) insulin and b) insulin plus Ziram on the LTQ
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Figure 3.11 Mass spectra of a) insulin a-chain and b) insulin a-chain plus Ziram
on the Q-Exactive
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Figure 3.12 Mass spectra of a) insulin b-chain and b) insulin b-chain plus Ziram
on the Q-Exactive
C
100
90

254

5733.6198
H 381 O 75 N

65

S

6

a)

Relative Abundance

80
70
60
50
40
5771.5597

30
20

5793.5182

10
C
100
90
80

254

5733.6144
H 381 O 75 N

65

S

6

b)

70
60
50
40
30

5921.5299

20
10
5720

5740

5760

5780

5800

5820
m/z

5840

5860

5880

5900

Figure 3.13 Mass spectra of a) insulin and b) insulin with Ziram on the QExactive
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CONCLUSION
In this experiment, the two ionization techniques APCI and ESI were
investigated as to which would be potentially better to detect Ziram on Liquid
Chromatography-Mass Spectrometer. Both positive and negative polarity for
each ionization technique was also investigated. Although all four modes,
positive APCI, negative APCI, positive ESI, and negative ESI, gave reproducible
results and would be good techniques to detect Ziram on the LC-MS, positive
ESI gave slightly better chromatography. It was deemed to be the better option
going forward. We then investigated the endogenous biomarkers glutathione and
insulin to see if Ziram bonded to either of them. Because Ziram has reactive
sulfurs, confirmation of where the binding was occurring was also investigated.
Ziram was definitively seen to create a disulfide bond with the cysteinic sulfur in
GSH via both the LTQ and QE. Although the LTQ and QE showed that Ziram
appeared to attach to the insulin, whether the attachment occurred at the
cysteines was not confirmed. Further research breaking down insulin more to
confirm the binding of Ziram to the cysteines is needed. However, after some
literature research, further experiments evaluated the Ziram and GSH interaction.
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CHAPTER 4. GLUTATHIONE AND ZIRAM METHOD DEVELOPMENT AND
VALIDATION USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
INTRODUCTION
Glutathione (γ-glutamyl-cysteinyl-glycine) is a thiol containing tripeptide that
is the most abundant low molecular weight peptide that was first identified over
100 years ago and the structure officially identified in 1935.34 The peptide is fairly
ubiquitous throughout animal tissues, plants, and microorganisms, accounting for
about 90% of the total nonprotein sulfurs within cells.34 Due to the highly reactive
sulfur on the cysteine, glutathione has been investigated as one of the most
prevalent antioxidant scavengers in the body. Although the molecular weight is
low (307.32 g/mol), the reactive sulfur and design of the peptide creates an
interesting candidate as a redox buffer, maintaining enzymes and other cellular
components in a reduced state. The glutamic acid is attached via the gamma
linkage, which could protect the peptide from degradation by aminopeptidases.35
Glutathione (GSH) is synthesized intracellularly beginning with the
attachment of γ-glutamic acid to cysteine via γ-glutamyl-cysteine synthetase.36,37
Glycine is then added onto the carboxyl side to γ-glutamyl-cysteine via
glutathione synthetase.36,37 The first reaction is inhibited by GSH. Glutathione is
degraded extracellularly via γ-glutamyl transpeptidase and other dipeptidases
where γ-glutamic acid is transferred to free amino acids and cysteinylglycine can
be broken down to be replenished.36,37 These γ-glutamyl amino acids are
transported into cells where they are converted to 5-oxoproline and subsequently
glutamate via an ATP-dependent reaction (Figure 4.1).37
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Figure 4.1 Glutathione metabolism.37 Enzymes include: 1, γ-glutamylcysteine
synthetase; 2, GSH synthetase; 3, γ-glutamyltranspeptidase; 4, dipeptidases; 5,
γ-glutamylcyclotransferase; 6, 5-oxoprolinase; 7, GSH S-transferases; 8, Nacetyltransferase; 9, GSH thiol transferases
Glutathione and diseases
Glutathione is one of the most important and abundant low molecular
weight antioxidants in the human body because of the electronegative sulfur side
chain on the cysteine.38 GSH plays an important role in many cellular reactions,
including scavenging free radicals and reactive oxygen species, storage and
transport of cysteine, and mitochondrial function and integrity to name a few.10,39
Because of these many functions, especially oxidative stress, glutathione has
been implicated as a biomarker in many diseases such as Parkinson’s Disease.
As an antioxidant, reduced glutathione is converted to the oxidized form, GSSG
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(Figure 4.1). Normally, GSSG is then reduced back to GSH by glutathione
reductase, but under oxidative stress, there is an accumulation of the oxidized
form.27 Not only does the accumulation of GSSG activate nuclear factor kappa B
(NF-κB) causing stress and inflammatory response, but the inability for GSSG to
convert back to GSH can cause other detrimental factors. These responses have
been implicated in many diseases including Parkinson’s.27,40 Thus, glutathione
has shown to be a potential biomarker in many diseases. In chapter 3, the
fungicide Ziram was investigated and glutathione was identified as a good
endogenous biomarker to detect the fungicide in further studies. In this
experiment, we investigated a method to determine glutathione’s binding to
Ziram using High Performance Liquid Chromatography-Mass Spectrometry.

MATERIALS AND METHODS
The Shimadzu Nexera Liquid Chromtography system coupled to the
Thermo Q-Exactive Orbitrap Mass Spectrometer was used. Both infusion and the
HPLC were utilized. The column used for the HPLC was a Kromasil Eternity XT2.5-C18 column with dimensions 2.1 x 100 mm. The QE infusion parameters
were similar to those referenced in chapter 3. When the LC was utilized the spray
voltage was 3 kV, the source current was 6.5-7 μA, the auxiliary sheath gas flow
was 10 arbitrary units, and a flow rate of 3 μL per minute.

Derivatization of glutathione with N-ethylmaleimide
Following the protocol by Giustarini et al, N-ethylmaleimide (500 μL of 155
mM) was combined with GSH (500 μL of 8 mM) in 50:50 MeOH:H2O and allowed
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to sit in the dark at room temperature for 45 minutes.41 The solution was diluted
by 100 and 1000 before infusion on the Q-Exactive. The NEM was later diluted to
50 mM and combined that with the 8 mM GSH before incubating in the dark at
room temperature for 45 minutes. At time intervals of 5, 15, 30, and 45 minutes,
10 μL of the solution was removed, diluted to 1000 μL 50:50 MeOH:H2O, and
infused on the Q-Exactive.
To determine if NEM would remove ZIR from GSH, a 1 mg/mL solution of
GSH-ZIR was first infused on the Q-Exactive for a control. Then, an equal
amount of NEM was added to the GSH-ZIR solution and allowed to sit at room
temperature in the dark for 45 minutes before infusion.

Extraction optimization and HPLC run
The preliminary extraction was 50 μL GSH-ZIR-NEM solution, 50 μL
acetonitrile, and 50 μL serum. Then the extraction included 50 μL GSH-ZIR, 50
μL glutathione-NEM (GSH-NEM), 50 μL 500 mM ammonium acetate, 50 μL
serum, and 100 μLacetonitrile. Final extraction ratio was 50 μL GSH-ZIR, 50 μL
GSH-NEM, 50 μL glutathione ethyl ester-NEM (GSE-NEM), 50 μL serum, 50 μL
500 mM ammonium acetate, and 50 μL 10% trichloroacetic acid (TCA). All
extractions were vortexed and centrifuged at 13.2 g in a microcentrifuge for 10
minutes. Supernatants were then collected into autosampler vials and injected on
the HPLC.
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For the LC run, the mobile phases were water with 0.1% formic acid as
mobile phase A and acetonitrile with 0.1% formic acid as mobile phase B. The
time gradient is seen in Table 4.1 and the flow rate was 0.3 mL/min.
Table 4.1 HPLC time gradient
Time
Mobile phase B %
0 min
5%
5 min
5%
7min
95%
10 min
95%
11 min
5%
15 min
Stop
Validation
For the method detection limit, we followed the protocol set by the
Environmental Protection Agency.42 Using the extraction method determined
earlier, we spiked in 50 nM GSH-ZIR, 50 nM GSH-NEM, and 50 μM GSE-NEM
into serum for seven replicates on three separate days. We also included seven
method blanks with each run. To determine the curves for both compounds, at
least five points in the range of 5 nM to 2 mM were evaluated over at least three
days.

RESULTS AND DISCUSSION
Derivatization of glutathione with N-ethylmaleimide
In previous studies, glutathione has been noted to auto-oxidize to the
disulfide form in biological matrices.43 Because of this phenomenon, accurately
measuring the total levels of GSH can be difficult. In the Camera et al. review,
they discuss different studies that have dealt with the auto-oxidation issue with
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GSH.43 Some studies derivatized glutathione, reduced all oxidized glutathione
back to the reduced form, and others have forced the oxidation among other
potential pathways to account for measuring GSH levels. In this experiment,
similarly to chapter 2 with homocysteine, we decided to use the reducing and
derivatizing agent NEM. NEM has been shown in previous studies to essentially
force the disulfide back into the reduced form and prevent any free GSH from
auto-oxidizing in solution.44
After following the Giustarini et al. protocol where 155 mM of NEM was
reacted with 8 mM GSH and infused on the Q-Exactive, there was no indicative
oxidized glutathione peak (m/z 613.15).41 However, there was a large peak of
NEM (m/z 126.05) indicating that there was too much NEM in the solution. It
made sense that there was a plethora of NEM leftover since the ratio of GSH to
NEM was roughly 1:100. Because of the high amount of NEM left over in
solution, the ratio of GSH to NEM was lowered to about 1:5 with 8 mM GSH and
50 mM NEM.
After 8 mM GSH was reacted with 50 mM NEM, we wanted to determine
the earliest incubation time needed to see GSH and NEM reacting. The solution
sat at room temperature in the dark for 45 minutes with 10 μL removed at 5, 15,
30, and 45 minutes. The indicative peak of the GSH-NEM (Figure 4.2a)
compound (433.13 m/z) was seen as early as five minutes (Figure 4.2b).
However, at the same time, the NEM molecular ion m/z 126.05 (Figure 4.3) was
more abundant than the GSH-NEM ion. As the incubation time went on, the ratio
of the ions switched to where the GSH-NEM ion became more abundant than the
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NEM ion (Figure 4.2b and 4.3). Because the ratio was still 1:5 with an excess of
NEM, the NEM ion was still seen at the 45-minute mark, but just less abundant
than at the five-minute mark. The potential auto-oxidation of GSH was also
confirmed to not occur at any time point, proving that while NEM was in the
sample, GSSG did not appear (Figure 4.4). Although GSH-NEM was seen as
early as five-minute, to ensure that the GSH was fully reacting with NEM before
any analysis took place, all further GSH-NEM solutions were given at least 45
minutes incubation time in the dark at room temperature.
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Figure 4.2 a) Structure of GSH-NEM and b) Mass spectra of GSH-NEM ion
433.13 at 5, 15, 30, and 45 min
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Figure 4.3 Mass spectra of NEM ion 126.05 at 5, 15, 30, and 45 min
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Figure 4.4 Mass spectra of GSSG 613.15 at 5, 15, 30, and 45 min
One thing we had to take into consideration was how NEM would interact
with the GSH-ZIR solution, since NEM is known to break disulfide bonds. After
seeing that GSH-ZIR and GSH-NEM on the instrument individually, we took
GSH-ZIR and added NEM in equal amounts to ZIR. No matter how long the
solution was left to react, we did not see a reduction in GSH-ZIR along with an
increase in GSH-NEM (Figure 4.5, 4.6, 4.7, and 4.8). However, most of the
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solutions made had an excess of Ziram, so there were some peaks indicating
that Ziram bonded to NEM separately. Although these Ziram-NEM peaks did not
seem to affect the results, we used the GSH-NEM and GSH-ZIR reacted
solutions for validation purposes.

Figure 4.5 Mass spectra of GSH-ZIR ion 427.07 before and after addition of NEM
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Figure 4.6 Mass spectra of glutathione ion 308.09 before and after addition of
NEM
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Figure 4.7 Mass spectra of NEM-ZIR ion 247.05 before and after addition of NEM
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Figure 4.8 Mass spectra of GSH-NEM ion 433.13 before and after addition of
NEM
Extraction optimization and HPLC run
When evaluating an extraction protocol, a few things had to be taken into
consideration. In terms of the matrix used, the main consideration was how to
actually remove the compounds from the matrix. In the review by Monostori et al,
they discussed different extractions techniques that have been used to remove
both reduced and oxidized glutathione from biological matrices.45 Overall, the
general extraction methods discussed involved the matrix and compounds of
interest and then some chemical or solution that would cause the proteins in the
matrix to precipitate out. Based on the Monostori et al. review, acetonitrile
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seemed like a viable starting point.45 The preliminary extraction used was 50 μL
of a GSH-NEM-ZIR solution, 50 μL acetonitrile, and 50 μL serum. The solution
was vortexed and centrifuged for 10 minutes before the supernatant was injected
on the HPLC with a 50 mm C18 column with water with 0.1% formic acid and
acetonitrile with 0.1% formic acid as the mobile phases. Because the compounds
are fairly polar and the column was believed to be short, none of the compounds
appeared in the chromatography. After switching to a longer column (100 mm),
the ions for the compounds were seen. The retention times were GSH (308.09
m/z) at 3.65 and 4.31 min, GSH-NEM (433.13 m/z) at 3.63 and 4.32 min, and
GSH-ZIR (433.13 m/z) at 7.36 min. Because the GSH and GSH-NEM peaks
split, parts of the HPLC run were evaluated. However, some literature has
reported that GSH-NEM causes split peaks due to the isomers forming from how
the NEM attaches to the GSH.46
Other studies believed that the split peaks were caused by something in the
extraction, so a buffer was included to balance out the pH.45 Ammonium acetate
was chosen as the buffer, which led to the extraction being 50 μL 500 mM
ammonium acetate, 50 μL of each compound, 50 μL serum, and 100 μL
acetonitrile for a total of 300 μL solution. After ammonium acetate was added, the
supernatant appeared more clear than before. In addition, the HPLC flow rate
was lowered to 0.2 mL/min to see if that also would help in the chromatography
of the molecules. The chromatography was a little bit cleaner, but the peak for
GSH-NEM was still split. The split peaks were still attributed to the isomers of
GSH-NEM. Looking forward to being able to quantitate the molecules a little
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better, a tandem experiment was done on the molecular weight ions of 427.07
m/z and 433.13 m/z for GSH-ZIR and GSH-NEM, respectively. The major
tandem ion for 427.07 was 251.08, as seen in Figure 4.9. The major tandem ions
for 433.13 are seen in Figure 4.10.
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Figure 4.9 Tandem spectrum of GSH-ZIR m/z 427.07
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Figure 4.10 Tandem spectrum of GSH-NEM m/z 433.13
Although GSH-ZIR and GSH-NEM were qualitatively seen, to add an extra
layer of sensitivity, an internal standard was evaluated to effectively quantitate
the two compounds. When looking for an internal standard, one should be as
physiochemically similar to the compound of interest and added to both
calibrators and samples at a known constant concentration to be able to use as a
comparison for the compound in question.26 An internal standard allows for any
type of error that could affect the variability between samples to be removed
because what happens to the molecule of interest should also occur to the
internal standard. Preferentially, an isotopically-labelled version of the molecule
in question should be used. In this study, we were unable to use an isotopically
labelled glutathione; however, we were able to use a similar compound,
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glutathione ethyl ester (GSE). The only difference between GSH and GSE is
instead of a carboxylic acid on the glycine end there is an ethyl ester (see Figure
4.11). Because of this being the only difference, both compounds are very similar
physiochemically. This also caused pause because of the reactive thiol group.
GSE was also derivatized with NEM to ensure that there were no interactions
between GSE and any other thiols, like GSH. When GSE was derivatized with
NEM, the molecular weight was 460.05 g/mol. The derivatization also allowed
GSE-NEM to more closely resemble GSH-NEM and all previous protocols for
derivatizing GSH with NEM was used to derivatize GSE with NEM. One issue
that was noted was that when tandem experiments were done on GSH-NEM and
GSE-NEM, similar tandem spectra was seen. Because of the ethyl ester instead
of the carboxylic acid, the main fragment ion for GSE-NEM was 315.10, which
was not seen in the GSH-NEM tandem spectrum and thus taken into
consideration with any tandem quantitation (Figure 4.12).
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Figure 4.11 Structure of GSH (top) and GSE (bottom)
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Figure 4.12 Tandem spectrum of GSE-NEM m/z ion 461.17
After the addition of the internal standard, the split peaks were reevaluated.
The HPLC parameters of the flow rate, mobile phases, and gradient were first
investigated to see if that would change the chromatography. The flow rate was
adjusted to 0.3 mL/min, 0.2 mL/min, and 0.25 mL/min. The change in flow rate
did not help the split peaks issue but only changed the retention times. For the
mobile phase, the formic acid was removed from mobile phase B. There was one
sample where the GSE-NEM did not have split peaks but the GSH-NEM still did.
In future work, we may look at removing the formic acid from both mobile phases.
Since the molecules eluted within ten minutes, the gradient was not adjusted
drastically. Even changing the starting conditions to 10% mobile phase B did not
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resolve the split peak issue. Because the HPLC settings did not seem to affect
the chromatography, the extraction parameters were evaluated some more.
First, the buffer was evaluated. Ammonium acetate (pH 6.4) and sodium
phosphate buffer (pH 7.2) were investigated as potential buffers. When the
sodium phosphate buffer was used in the extraction, the peaks did not split, but
the GSH-NEM and GSH-ZIR came out in the void volume. The sodium in the
buffer most likely created an adduct with the compounds. To prevent adduct
formation and since the chromatography was poor, ammonium acetate was still
used in the extractions. The extraction ratio of ammonium acetate to acetonitrile
was then assessed. The ratios of ammonium acetate to acetonitrile were 1:2, 1:1,
and 2:1. With the 2:1 ratio, the GSH-NEM and GSH-ZIR still had two peaks, but
were baseline resolved. GSE-NEM still had split peaks, especially near the later
samples. Even though a couple runs would appear okay, the samples were not
reproducible enough to stick with a particular extraction. Previous studies have
used other protein precipitation solvents, like sulfosalicylic acid and
trichloroacetic acid, usually at a concentration of 10%.41 We included some of the
changes that were previously investigated with 10% trichloroacetic acid (TCA). A
majority of the chromatograms for the different extraction types are in Figure 4.13
for GSH-ZIR, Figure 4.14 for GSE-NEM, and Figure 4.15 for GSH-NEM. Over all
three compounds, the best chromatography came from the extraction that
involved 50 μL of each compound, 50 μL 500 mM ammonium acetate, 50 μL
serum, and 50 μL 10% TCA. The retention times were around 7.30 minutes for
GSH-ZIR, 5.50 minutes for GSH-NEM, and 7.60 minutes for GSE-NEM.
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Figure 4.13 Chromatograms of different extractions for GSH-ZIR. a) original
extraction, no TCA; b) TCA without acetonitrile; c) TCA with acetonitrile; d) TCA,
sodium phosphate buffer, no acetonitrile; e) TCA, sodium phosphate buffer,
acetonitrile; f) TCA, acetonitrile, formic acid in mobile phase; g) TCA, no
acetonitrile, formic acid in mobile phase
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Figure 4.14 Chromatograms of different extractions for GSH-NEM. a) original
extraction, no TCA; b) TCA without acetonitrile; c) TCA with acetonitrile; d) TCA,
sodium phosphate buffer, no acetonitrile; e) TCA, sodium phosphate buffer,
acetonitrile; f) TCA, acetonitrile, formic acid in mobile phase; g) TCA, no
acetonitrile, formic acid in mobile phase
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Figure 4.15 Chromatograms of different extractions for GSE-NEM. a) original
extraction, no TCA; b) TCA without acetonitrile; c) TCA with acetonitrile; d) TCA,
sodium phosphate buffer, no acetonitrile; e) TCA, sodium phosphate buffer,
acetonitrile; f) TCA, acetonitrile, formic acid in mobile phase; g) TCA, no
acetonitrile, formic acid in mobile phase
Validation
Glutathione has previously been detected at levels in biological matrices
ranging from low micromolar range to low millimolar range.10,41 However, since
most of the research with Ziram is via epidemiology studies and there is no
definitive concentration seen consistently in biological matrices, we erred on the
side of caution and decided to try to detect in the nanomolar range with GSH-ZIR
and GSH-NEM. Although GSH is normally in the micromolar range, being able to
detect GSH-ZIR at lower levels could potentially lead to early detection of
diseases caused by Ziram.
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For the calibration curve, we wanted to cover a large range of values, so
we created a curve from 5 nM to 2 mM. For both GSH-ZIR and GSH-NEM, 50
uM of GSE-NEM was used as the internal standard concentration. At first nine
points were used for the calibration curve, but after removing outliers, a six-point
curve was used for the GSH-NEM curve. The points were 5 nM, 100 nM, 500
nM, 1 μM, 100 μM, and 500 μM. Because normal GSH ranges do not go very
high, only up to 500 μM was included in the curve. There was a curve done on
three different days to account for inter-day variability. For GSH-NEM, the
averaged calibration points gave a curve with a R2 value of 0.9998, as seen in
Figure 4.16.

Figure 4.16 Calibration curve of GSH-NEM
The next validation parameter that was evaluated was the method
detection limit (MDL). The MDL is described “as the minimum measured
concentration of a substance that can be reported with 99% confidence that the
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measured concentration is distinguishable from method blank results.”42 This is
done by spiking anywhere from two to 10 times the amount of the limit of
detection (LOD) in the matrix of choice for seven replicates over three days. The
method detection limit is then calculated by the spiked standard deviation value
times the student t-value at the 99% confidence interval. Because our intended
LOD was set to 5 nM, the spiked concentration used was 50 nM. For the purpose
of the MDL, the samples were ran in full scan. The method detection limit for
GSH-NEM was determined to be 1.47 μM. The ratio of area counts of 433.13 to
461.16 was first determined over at least 3 days. Those values were then solved
for the concentration based on the calibration curve equation of
y=0.0027x+0.0015 (Figure 4.16) where y is the ratio and x is the concentration.
Each day’s seven samples were then averaged and the standard deviation was
taken (Ss). This standard deviation was then multiplied by 3.143 which is the 99%
confidence level of the student’s t-test with n=7 (Equation 1). Each one of those
values was then averaged giving the 1.47 μM. This procedure was also done for
seven blanks over at least three separate days (Equation 2). The standard
deviation of the blanks was multiplied by the 3.143 value again and added to the
average concentration of the blanks. Whichever value was highest, the MDLs or
MDLb,was the given method detection limit. For GSH-NEM, the blanks gave a
negative value, making 1.47 μM the method detection limit.
𝑀𝑀𝑀𝑀𝑀𝑀𝑠𝑠 = 𝑡𝑡(𝑛𝑛−1,1−𝛼𝛼=.99) 𝑆𝑆𝑠𝑠

𝑀𝑀𝑀𝑀𝑀𝑀𝑏𝑏 = 𝑋𝑋� + 𝑡𝑡(𝑛𝑛−1,1−𝛼𝛼=.99) 𝑆𝑆𝑏𝑏
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(𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝑖𝑖𝑖𝑖𝑖𝑖 1)

(𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 2)

CONCLUSION
In this study, further investigation of glutathione and Ziram occurred. Similarly
to chapter 2 about homocysteine, N-ethylmaleimide was used as a derivatizing
agent to prevent the auto-oxidation of GSH in biological matrices. Although GSHZIR and GSH-NEM were seen with sufficient reproducibility, glutathione ethyl
ester was implemented as an internal standard to account for any variability
between samples. To prevent the cysteine from reacting with free thiols, GSE
was also derivatized with NEM. Using GSE-NEM as the internal standard, the
extraction method and HPLC parameters were evaluated to create a better
extraction and to potentially prevent split peaks that were seen with GSH-NEM.
Although the extraction was somewhat cleaned up and the split peaks were
resolved in some samples, further work should be done to complete this
optimization. After the initial optimization, the method validation began. There
were some issues with validating GSH-ZIR, so we worked on validating GSHNEM. A curve from 5 nM to 500 μM was created with a R2 value of 0.9998. The
method detection limit for GSH-NEM was also evaluated and determined to be
1.47 μM. Further validation parameters would need to be evaluated and a full
validation of GSH-ZIR is also needed in future work.
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CHAPTER 5. CONCLUSIONS AND FUTURE WORK
As people become more aware of the impact that environmental exposures
have on their overall health, there is a growing need to be at the forefront to
determine potential biomarkers for the development of diseases. In this work, two
endogenous biomolecules that have been implicated in the development of
diseases and disorders were investigated. The first was homocysteine, which
was successfully identified via capillary electrophoresis. Because it was hard to
differentiate between similar thiol-containing amino acids, homocysteine was
derivatized with 4-vinyl pyridine and N-ethylmaleimide. The derivatization with
NEM was confirmed via capillary electrophoresis-mass spectrometry. The other
endogenous biomarker was glutathione, the most abundant low-molecular weight
thiol-containing molecule. First, glutathione was shown to bind to the fungicide
Ziram via the cysteine thiol. Because Ziram is a part of the larger dithiocarbamate
family, this work could lead to further studies on these compounds. An extraction
protocol was evaluated, and early validation was done for GSH-ZIR, GSH-NEM,
and the internal standard glutathione ethyl ester-NEM in serum. Like
homocysteine, GSH was derivatized with NEM to account for extra GSH in
biological matrices. The internal standard GSE was also derivatized with NEM to
prevent any bonding with GSH or other thiols. A curve for GSH-NEM was
developed from 5 nanomolar to 500 micromolar. The method detection limit was
determined at the 5 nanomolar level to be 1.47 micromolar.
For future work, more work should be done on homocysteine. Potentially,
a method could be developed and validated for homocysteine. Although Ziram
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was only looked at in terms of glutathione, more work could be done to look at
other endogenous biomarkers, like homocysteine, and how Ziram interacts with
them, leading to diseases. Further validation needs to be done on GSH-NEM and
GSH-ZIR. Other biological matrices and fungicides would be investigated and
validated, including blood and plasma. After development of the methods, the
long-term goal was to investigate the connection of these environmental
exposures, endogenous biomarkers, and the development of diseases. This work
is a starting point for many more exposure studies to potentially help people be
more aware of how their environment can affect their health and have the
potential for disease development throughout their life.
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